Get started
Author

Anjan Thakurta

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
2013 · Anita K. Gandhi, Jian Kang, et al. · British Journal of Haematology · 615
PDF
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
2016 · Nikhil C. Munshi, Herve Avet-Loiseau, et al. · JAMA Oncology · 540
PDF
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
2018 · Brian A. Walker, Konstantinos Mavrommatis, et al. · Blood · 474
PDF
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
2018 · Brian A. Walker, Konstantinos Mavrommatis, et al. · Leukemia · 446
PDF
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
2017 · Michael D. Amatangelo, Lynn Quek, et al. · Blood · 359
PDF
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
2015 · C C Bjorklund, L Lu, et al. · Blood Cancer Journal · 221
PDF
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
2019 · Chad C. Bjorklund, Jian Kang, et al. · Leukemia · 203
PDF
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
2015 · Patrick R. Hagner, Hon-Wah Man, et al. · Blood · 198
PDF
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
2018 · Lynn Quek, Muriel D. David, et al. · Nature Medicine · 197
PDF
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
2020 · Sarah Gooding, Naser Ansari-Pour, et al. · Blood · 171
PDF
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2017 · Myron S. Czuczman, Marek Trněný, et al. · Clinical Cancer Research · 162
PDF
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
2015 · Kartik Sehgal, Rituparna Das, et al. · Blood · 132
Nanopore sequencing of single-cell transcriptomes with scCOLOR-seq
2021 · Martin Philpott, Jonathan Watson, et al. · Nature Biotechnology · 116
PDF
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
2019 · Anjan Thakurta, Maria Ortiz, et al. · Blood · 114
PDF
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
2013 · Anita K. Gandhi, Derek Mendy, et al. · British Journal of Haematology · 106
PDF
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
2020 · Erin Flynt, Kamlesh Bisht, et al. · Cells · 78
PDF
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
2015 · Eytan M. Stein, Courtney DiNardo, et al. · Blood · 72
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
2020 · Mehmet Kemal Samur, Anil Aktas Samur, et al. · Journal of Clinical Oncology · 70
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
2018 · Laurens E. Franssen, Inger S. Nijhof, et al. · Haematologica · 65
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
2019 · Aneta Mikulasova, Cody Ashby, et al. · Haematologica · 63
Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma
2016 · Emily Rychak, Derek Mendy, et al. · British Journal of Haematology · 60
PDF
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer
2022 · Nicole E. Pellegrino, Arcan Guven, et al. · International Journal of Molecular Sciences · 57
PDF
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
2021 · Anjan Thakurta, William E. Pierceall, et al. · Oncotarget · 56
PDF
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
2013 · A Thakurta, A K Gandhi, et al. · Leukemia · 56
PDF
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
2020 · Mike J. Mason, Carolina Schinke, et al. · Leukemia · 52
PDF
Works count: 304
Citation count: 5,910
H-index: 35
I10-index: 67
Year
Topic
Type